ATOM study met the primary endpoint of change in lumbar spine bone mineral density at 12 months (p-value < 0.0001) Study also met secondary endpoints relating to bone mineral density changes in lumbar ...
Alfredo has a PhD in Astrophysics and a Master's in Quantum Fields and Fundamental Forces from Imperial College London.View full profile Alfredo has a PhD in Astrophysics and a Master's in Quantum ...
BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided a business progress and regulatory update. On February 25, 2022, the Company filed a ...
Radius Health, Inc. RDUS announced positive top-line data from the phase III ATOM study which is evaluating its lead product, Tymlos (abaloparatide 80 mg subcutaneous [“SC”]) injection, for use in men ...
Radius Health, Inc. (Radius) announced that the US Food and Drug Administration (FDA) has approved Tymlos (abaloparatide), a parathyroid hormone related peptide [PTHrP(1-34)] analog, as a treatment to ...
Radius Reports Positive Phase 3 Results For TYMLOS Subcutaneous Injection In Males With Osteoporosis
(RTTNews) - Radius Health Inc. (RDUS) announced positive results from the ATOM Phase 3 Study evaluating TYMLOS or abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback